KR20220104744A - 감염성 질환을 치료하기 위한 소분자 푸린 억제제 - Google Patents
감염성 질환을 치료하기 위한 소분자 푸린 억제제 Download PDFInfo
- Publication number
- KR20220104744A KR20220104744A KR1020227019647A KR20227019647A KR20220104744A KR 20220104744 A KR20220104744 A KR 20220104744A KR 1020227019647 A KR1020227019647 A KR 1020227019647A KR 20227019647 A KR20227019647 A KR 20227019647A KR 20220104744 A KR20220104744 A KR 20220104744A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- pyridin
- oxy
- dichlorophenyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934407P | 2019-11-12 | 2019-11-12 | |
| US62/934,407 | 2019-11-12 | ||
| PCT/US2020/060108 WO2021097009A1 (en) | 2019-11-12 | 2020-11-12 | Small molecule furin inhibitors for treating infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220104744A true KR20220104744A (ko) | 2022-07-26 |
Family
ID=73793799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227019647A Ceased KR20220104744A (ko) | 2019-11-12 | 2020-11-12 | 감염성 질환을 치료하기 위한 소분자 푸린 억제제 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230011571A1 (https=) |
| EP (1) | EP4058021A1 (https=) |
| JP (1) | JP2023503852A (https=) |
| KR (1) | KR20220104744A (https=) |
| CN (1) | CN114929220A (https=) |
| AU (1) | AU2020382819A1 (https=) |
| CA (1) | CA3157892A1 (https=) |
| WO (1) | WO2021097009A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020022961A2 (pt) | 2018-05-11 | 2021-02-17 | Glaxosmithkline Intellectual Property Development Limited | inibidores de furina |
| DE102023126563A1 (de) * | 2023-09-28 | 2025-04-03 | Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts | Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037346A1 (en) * | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| EP2478766A3 (en) | 2007-05-09 | 2012-08-15 | Burnham Institute for Medical Research | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
| US20150051138A1 (en) * | 2012-03-16 | 2015-02-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| US10150742B2 (en) * | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| CN107441094B (zh) * | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| BR112020022961A2 (pt) * | 2018-05-11 | 2021-02-17 | Glaxosmithkline Intellectual Property Development Limited | inibidores de furina |
-
2020
- 2020-11-12 KR KR1020227019647A patent/KR20220104744A/ko not_active Ceased
- 2020-11-12 AU AU2020382819A patent/AU2020382819A1/en active Pending
- 2020-11-12 JP JP2022527989A patent/JP2023503852A/ja active Pending
- 2020-11-12 CA CA3157892A patent/CA3157892A1/en active Pending
- 2020-11-12 CN CN202080092431.9A patent/CN114929220A/zh active Pending
- 2020-11-12 EP EP20823987.1A patent/EP4058021A1/en active Pending
- 2020-11-12 US US17/776,067 patent/US20230011571A1/en not_active Abandoned
- 2020-11-12 WO PCT/US2020/060108 patent/WO2021097009A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20230011571A1 (en) | 2023-01-12 |
| CA3157892A1 (en) | 2021-05-20 |
| EP4058021A1 (en) | 2022-09-21 |
| JP2023503852A (ja) | 2023-02-01 |
| WO2021097009A1 (en) | 2021-05-20 |
| CN114929220A (zh) | 2022-08-19 |
| AU2020382819A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2898069T3 (es) | Derivados de N-(piridin-2-il)piridinosulfonamida y su uso en el tratamiento de la enfermedad | |
| CN105431420B (zh) | 二杂芳基化合物及其用途 | |
| TW202322810A (zh) | 作為kras抑制劑之喹啉化合物 | |
| KR102823187B1 (ko) | 푸린 억제제 | |
| AU2015339196A1 (en) | Substituted tetrahydropyrans and method of use | |
| AU2009274027A1 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| EP2632260A1 (en) | Leucine-rich repeat kinase enzyme activity | |
| WO2024057013A1 (en) | Nlrp3 modulators | |
| IL273237B1 (en) | New heterocyclic compounds as mglur7 modulators | |
| CN105399756B (zh) | Btk抑制剂及其用途 | |
| WO2020011147A1 (en) | RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE | |
| CN111704615A (zh) | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 | |
| KR20220104744A (ko) | 감염성 질환을 치료하기 위한 소분자 푸린 억제제 | |
| WO2022048498A1 (zh) | Usp7抑制剂 | |
| KR20210005569A (ko) | Rsv에 대한 활성을 갖는 헤테로방향족 화합물 | |
| US20260015360A1 (en) | Biaryl derivatives and related uses | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| CN104530046B (zh) | 二氮杂螺类化合物及其在药物中的应用 | |
| WO2021097002A1 (en) | Use of pyridyloxypyrimidines for treating infectious diseases | |
| WO2021097008A1 (en) | Use of pyridyloxypyridines for treating infectious diseases | |
| RU2799824C2 (ru) | Ингибиторы фурина | |
| WO2025155786A1 (en) | Bicyclic tyrosine kinase 2 inhibitors and uses thereof | |
| WO2025126115A1 (en) | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use | |
| WO2025228367A1 (en) | Pde3a/slfn12 disruptors, preparations, and uses thereof | |
| TW202543612A (zh) | 噻吩并吡啶化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |